Review



cells adherent ovarian cancer cell lines ovcar 8  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    ATCC cells adherent ovarian cancer cell lines ovcar 8
    Cells Adherent Ovarian Cancer Cell Lines Ovcar 8, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1101 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cells adherent ovarian cancer cell lines ovcar 8/product/ATCC
    Average 97 stars, based on 1101 article reviews
    cells adherent ovarian cancer cell lines ovcar 8 - by Bioz Stars, 2026-05
    97/100 stars

    Images



    Similar Products

    cells adherent ovarian cancer cell lines ovcar 8  (ATCC)
    97
    ATCC cells adherent ovarian cancer cell lines ovcar 8
    Cells Adherent Ovarian Cancer Cell Lines Ovcar 8, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cells adherent ovarian cancer cell lines ovcar 8/product/ATCC
    Average 97 stars, based on 1 article reviews
    cells adherent ovarian cancer cell lines ovcar 8 - by Bioz Stars, 2026-05
    97/100 stars
    		  Buy from Supplier
    adherent ovarian cancer cell lines ovcar 8  (ATCC)
    97
    ATCC adherent ovarian cancer cell lines ovcar 8
    Combinatorial treatment effect of olaparib and GW in a translational approach using primary <t>OvCa</t> spheroids. Primary cells from two BRCA 1 (UF-364; UF-510) and one BRCA 2 mutated patient (UF-357) were grown as spheroids in ULA plates and analyzed for their response to olaparib and additional treatment either GI or GW. The solvent DMSO has been used as a control. (A) Relative (rel.) caspase activity was increased following treatment with olaparib and GW compared to olaparib mono-treatment. Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. (B) Representative Brightfield (left) and CellTox Green (right) images of UF-357; UF-364 and UF-510 following the indicated treatment conditions, which generated the strongest combinatorial effect are displayed (UF-357: 0/100 µM olaparib; UF-364: 0/10 µM olaparib; UF-510: 0/200 µM olaparib). Scalebar: 250 μm.
    Adherent Ovarian Cancer Cell Lines Ovcar 8, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/adherent ovarian cancer cell lines ovcar 8/product/ATCC
    Average 97 stars, based on 1 article reviews
    adherent ovarian cancer cell lines ovcar 8 - by Bioz Stars, 2026-05
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    Combinatorial treatment effect of olaparib and GW in a translational approach using primary OvCa spheroids. Primary cells from two BRCA 1 (UF-364; UF-510) and one BRCA 2 mutated patient (UF-357) were grown as spheroids in ULA plates and analyzed for their response to olaparib and additional treatment either GI or GW. The solvent DMSO has been used as a control. (A) Relative (rel.) caspase activity was increased following treatment with olaparib and GW compared to olaparib mono-treatment. Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. (B) Representative Brightfield (left) and CellTox Green (right) images of UF-357; UF-364 and UF-510 following the indicated treatment conditions, which generated the strongest combinatorial effect are displayed (UF-357: 0/100 µM olaparib; UF-364: 0/10 µM olaparib; UF-510: 0/200 µM olaparib). Scalebar: 250 μm.

    Journal: Scientific Reports

    Article Title: Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids

    doi: 10.1038/s41598-024-78442-y

    Figure Lengend Snippet: Combinatorial treatment effect of olaparib and GW in a translational approach using primary OvCa spheroids. Primary cells from two BRCA 1 (UF-364; UF-510) and one BRCA 2 mutated patient (UF-357) were grown as spheroids in ULA plates and analyzed for their response to olaparib and additional treatment either GI or GW. The solvent DMSO has been used as a control. (A) Relative (rel.) caspase activity was increased following treatment with olaparib and GW compared to olaparib mono-treatment. Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. (B) Representative Brightfield (left) and CellTox Green (right) images of UF-357; UF-364 and UF-510 following the indicated treatment conditions, which generated the strongest combinatorial effect are displayed (UF-357: 0/100 µM olaparib; UF-364: 0/10 µM olaparib; UF-510: 0/200 µM olaparib). Scalebar: 250 μm.

    Article Snippet: Adherent ovarian cancer cell lines OVCAR-8 (RRID: CVCL_1629 ) , IGROV-1 (RRID: CVCL_1304) and SKOV-3 (RRID: CVCL_0532), purchased from American Type Culture Collection (ATCC) were grown with RPMI-1640 medium containing 10% fetal bovine serum (Gibco Life Technologies), 1% L-Glutamine (Sigma-Aldrich, St. Louis, MO, USA) and penicillin-streptomycin (3000 U pen./30,000 μg str. per 500 mL RPMI-1640; Biochrom).

    Techniques: Solvent, Control, Activity Assay, CellTox Assay, Generated